Repository logo
  • English
  • äø­ę–‡
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • äø­ę–‡
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pureå­øč”“äŗŗę‰åŗ«č½‰å…„
  4. Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma
 
  • Details
Options

Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma

Journal
Targeted Oncology
Date Issued
2024-11-01
Author(s)
KUN-CHIEH CHEN  
SHENG-YI LIN  
GEE-CHEN CHANG  
DOI
10.1007/s11523-024-01104-6
URI
https://www.scopus.com/pages/publications/85206676473
https://scholars.csmu.edu.tw/handle/123456789/25647
Abstract
Background: The clinical outcomes of patients with anaplastic lymphoma kinase-positive (ALK+) advanced lung adenocarcinoma vary according to real-world data. Objective: In this study, we aimed to investigate the treatment discontinuation (TTD) and overall survival (OS) of patients with ALK+ advanced lung adenocarcinoma treated with first-line ALK–TKIs in Taiwan. Patients and Methods: This retrospective study evaluated all advanced lung adenocarcinoma patients registered in the National Taiwan Cancer Registry from 2017 to 2020 who had ALK rearrangement and received ALK–TKI treatment, using data from Taiwan’s National Health Insurance Research Database (NHIRD). The TKI treatment sequences were classified into first generation (G1: crizotinib), second generation (G2: ceritinib, alectinib, brigatinib), and third generation (G3: lorlatinib). Results: A total of 587 patients were analyzed, with a median age of 60.0 years, 91 (15.5%) aged ≄ 74 years, 293 (49.9%) female, 397 (67.6%) never smoked, and 534 (91.0%) with stage IV disease. Patients who received next-generation ALK–TKIs during the treatment course had longer median time to ALK–TKI TTD and OS. The TTD of the G1, G1+2, G1+2+3, G2, and G2+3 groups was 7.5 (5.4–11.1), 40.6 (29.4–not calculated (NC)), 50.3 (41.3–NC), 34.3 (29.2–43.0), and 36.3 (22.4–NC) months, respectively (p < 0.001). The median OS of the patients in the G1, G1+2, G1+2+3, G2, and G2+3 groups was 10.6 (7.5–14.6), not reached (NR) (NC–NC), NR (NC–NC), 43.0 (36.3–NC), and NR (30.3–NC) months, respectively (p < 0.001). Compared with treatment with crizotinib alone, the multivariate analysis revealed that treatment with next-generation TKIs was independently associated with longer TTD (G1+2 (hazard ratio (HR), 0.24; 95% CI 0.17–0.33; p < 0.001), G1+2+3 or G1+3 (HR, 0.17; 95% confidence interval (CI), 0.10–0.28; p < 0.001), G2 (HR, 0.26; 95% CI 0.19–0.36; p < 0.001), and G2+3 (HR, 0.25; 95% CI 0.14–0.44; p < 0.001)) and median OS (G12 (HR, 0.24; 95% CI 0.17–0.35; p < 0.001), G1+2+3 or G1+3 (HR, 0.09; 95% CI 0.04–0.21; p < 0.001), G2 (HR, 0.22; 95% CI 0.15–0.31; p < 0.001), and G2+3 (HR, 0.20; 95% CI 0.10–0.42; p < 0.001)). Conclusions: For patients with ALK+ NSCLC, treatments including next-generation ALK–TKIs were independently associated with longer survival outcomes.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback